World Wires · story 22160 · unverified · 1 source(s)

Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121

CAMBRIDGE, Mass., Oct. 05, 2026 (GLOBE NEWSWIRE) -- Korro Bio, Inc. (Korro) (Nasdaq: KRRO), a clinical-stage biopharmaceutical company leveraging its oligo

Open in the desk

Coverage

• Korro Announces First Cohort Dosed in Phase 1/2 Clinical Trial (ANCHOR) for KRRO-121 GlobeNewswire: public companies · tier D · clear net · 2026-10-05 20:05 UTC

What this site indexes